4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 78 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $240,294 | -60.2% | 11,448 | -39.6% | 0.00% | -100.0% |
| Q1 2024 | $604,289 | +51.0% | 18,967 | -4.4% | 0.00% | 0.0% |
| Q4 2023 | $400,072 | +105.7% | 19,835 | +29.8% | 0.00% | – |
| Q3 2023 | $194,489 | -25.6% | 15,278 | +5.7% | 0.00% | -100.0% |
| Q2 2023 | $261,256 | +26.3% | 14,458 | +20.1% | 0.00% | – |
| Q1 2023 | $206,899 | -16.7% | 12,036 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $248,423 | +22.4% | 12,036 | -10.5% | 0.00% | 0.0% |
| Q1 2022 | $203,000 | -28.5% | 13,443 | +7.2% | 0.00% | 0.0% |
| Q4 2021 | $284,000 | – | 12,538 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |